Cingulate Overview
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
CING
- Share Price
-
$3.74
- (As of Monday Closing)
Cingulate General Information
Description
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Contact Information
Website
www.cingulate.comCorporate Office
- 1901 West 47th Place
- Kansas City, KS 66205
- United States
Corporate Office
- 1901 West 47th Place
- Kansas City, KS 66205
- United States
Cingulate Timeline
Cingulate Stock Performance
As of 16-Nov-2026, Cingulate’s stock price is $3.74. Its current market cap is $56M with 15M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.74 | $4.33 | $3.16 - $11.89 | $56M | 15M | 124K | -$2.67 |
Cingulate Financials Summary
As of 30-Sep-2026, Cingulate has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 49,870 | 27,786 | 6,030 | 8,786 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,397) | (20,548) | (16,006) | (22,176) |
| Net Income | (29,187) | (22,450) | (16,560) | (23,535) |
| Total Assets | 28,151 | 15,073 | 14,864 | 3,491 |
| Total Debt | 4,535 | 8,787 | 5,099 | 3,510 |
Cingulate Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cingulate Comparisons
Industry
Financing
Details
Cingulate Competitors (13)
One of Cingulate’s 13 competitors is Citius Pharma, a Formerly Angel backed company based in Cranford, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Citius Pharma | Formerly Angel backed | Cranford, NJ | ||||
| Heron Therapeutics | Formerly VC-backed | Cary, NC | ||||
| PDX Pharmaceuticals | Venture Capital-Backed | Portland, OR | ||||
| Roivant Sciences | Formerly PE-Backed | New York, NY | ||||
| BBS Nanotechnology | Formerly VC-backed | Debrecen, Hungary |
Cingulate Patents
Cingulate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025091842-A | Information processing device, method, program, and system | Pending | 08-Dec-2023 | ||
| JP-2025091843-A | Information processing device, method, program, and system | Pending | 08-Dec-2023 | ||
| JP-2025091542-A | Information processing apparatus, method, program, and system | Pending | 07-Dec-2023 | ||
| JP-2025505781-A | Trimodal precision timed release tablets | Pending | 16-Feb-2022 | ||
| AU-2023222759-A1 | Trimodal, precision-timed release tablet | Pending | 16-Feb-2022 | A61K9/209 |
Cingulate Signals
Cingulate Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cingulate ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Cingulate FAQs
-
Where is Cingulate headquartered?
Cingulate is headquartered in Kansas City, KS.
-
What is the size of Cingulate?
Cingulate has 14 total employees.
-
What industry is Cingulate in?
Cingulate’s primary industry is Pharmaceuticals.
-
Is Cingulate a private or public company?
Cingulate is a Public company.
-
What is Cingulate’s stock symbol?
The ticker symbol for Cingulate is CING.
-
What is the current stock price of Cingulate?
As of 16-Nov-2026 the stock price of Cingulate is $3.74.
-
What is the current market cap of Cingulate?
The current market capitalization of Cingulate is $56M.
-
Who are Cingulate’s competitors?
Citius Pharma, Heron Therapeutics, PDX Pharmaceuticals, Roivant Sciences, and BBS Nanotechnology are some of the 13 competitors of Cingulate.
-
What is Cingulate’s annual earnings per share (EPS)?
Cingulate’s EPS for 12 months was -$2.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process